The next-generation peer-to-peer betting platform now lets users create their own bets — on sports, life, or whatever topic the group is discussing — and settle them straight from chat with zero fees between friends.

LOS ANGELES, Sept. 9, 2026 /PRNewswire/ -- Slips, the next-generation peer-to-peer betting platform, today announced the launch of Create Bet and Challenge — the most social product release in real-money gaming. Slips users can now create their own bets on anything, send them to friends through group chat, and settle them peer-to-peer with zero fees between friends.

The launch introduces a new social behavior: "slip me." Where friends today text "Venmo me" to split dinner, they can now text "slip me" to bet each other. On the game. On the golf outing. On whether their friend actually shows up tonight. Slips is where the bet lives, gets accepted, and pays out. All from chat.

"Every other operator in this space is doing the same thing with different logos — you against the house, on the same handful of markets," said Jess Richman, Founder & CEO of Slips. "We built Slips around how people actually bet each other in real life. On the game, sure. But also on the golf outing, on who's paying for drinks, on whether Billy shows up in the same jacket. That's real betting. That's what Slips is — where 'slip me' becomes a thing people actually say."

The launch includes:

- Create Bet. Users can now make their own bets on anything — sports, life, weird inside jokes — and send them straight to friends or groups. Whoever's right takes the pot.

- Group chat, upgraded. Chats now support images, reactions, and one-tap bet sending. Bets fire directly from the conversation.

- Zero fees between friends. Every bet between friends settles peer-to-peer with no platform fees, made possible by Slips' peer-to-peer architecture. Membership tiers may impact the number of free transactions.

- Zero-fee ACH deposits. Users can now fund their accounts via ACH with zero deposit fees.

Why it's different

For a decade, sports betting has looked the same: users pick from a fixed menu of sportsbook odds, the house sets the terms, the platform wins on the vig. Slips flips that structure. Users bet each other. The platform matches counterparties and processes settlement — but never takes a position against the players.

"The industry has been optimizing the same house-banked model since day one," Richman added. "Nobody asked the players what they actually want. What we see on Slips is clear: when you give people the tools to bet their friends on anything, they don't go back. They want to make their own bets. They want to talk trash in the chat. They want 'slip me' to be their new default. That's the whole point."

About Slips

Founded in 2021, Slips is the next-generation peer-to-peer betting platform where players bet against each other — not the house. Across bets, challenges, and predictions, Slips creates a social-first experience where users win, connect, and compete in real time — all through the chat and community they already trust.

Backed by leading venture capital firms, professional sports team owners, and more, Slips brings together a powerhouse group of investors aligned with its mission to redefine peer-to-peer betting.

SOURCE Slips Technologies, Inc.

Share this article

Amped Fitness First-Ever Amped Summer Creator Challenge Brings 2,000+ Creators and Awards $25,000 in Prizes

Joel "J.D." Valdez earns the $10,000 Grand Prize after his story of resilience stood out among thousands of videos and personal journeys shared throughout the summer

ST. PETERSBURG, Fla., Sept. 9, 2026 /PRNewswire/ -- Amped Fitness today announced Joel "J.D." Valdez as the $10,000 Grand Prize winner of Amped Summer, concluding a three-month creator challenge that brought together more than 2,000 creators competing for a $25,000 prize pool.

Launched in June as the first major activation of the Amped Creator Program, Amped Summer invited creators to take audiences inside their own experience with the brand. Throughout the summer, thousands of videos captured transformations, friendships, humor, training, personal milestones, setbacks, comebacks and stories that reached far beyond the gym.

Together, the content was seen more than 100 million times across social media, giving audiences a look at thousands of different journeys unfolding across the Amped community. Amped Fitness awarded $25,000 across 12 winners throughout the challenge.

"When we created the Creator Program, we knew there was an incredible community of people already creating around Amped, but we never expected a response like this," said Danyal Ali, Chief Marketing Officer of Amped Fitness. "More than 2,000 creators opened up their lives to us, and we loved seeing the creativity and the stories that came with it. There were so many that stood out, but J.D.'s journey was one we simply couldn't forget."

In 2021, Valdez, a Houston father and business owner, was leaving a grocery store when he was shot six times by a stranger. An innocent bystander, he suffered serious injuries, including gunshot wounds to his neck and shoulder, and remained hospitalized awaiting surgery as Houston-area hospitals faced extraordinary capacity constraints during the COVID-19 pandemic. His experience and recovery were documented by FOX 26 Houston.

Five years later, his Amped Summer submission offered a very different chapter of his life.

Valdez shared the long road back, including years of physical pain and the mental toll of the shooting, before eventually returning to the gym and beginning to rebuild his strength. He described progressing from struggling with weights as light as five and 10 pounds to nearly bench pressing his own body weight again.

Along the way, messages inside Amped became a personal reminder of how far he had come.

"What helps a lot is the things that you guys have chosen to put up on the walls. 'You vs. You, Stronger than Yesterday.' Every single time I'm in there, I look at it and it's a reminder," Valdez said.

His journey ultimately stood out among more than 2,000 participating creators, earning Valdez the $10,000 Grand Prize and making him the first Amped Summer champion.

"I can't tell you how many people have told me, 'You made it for a reason. You're here for a reason,'" Valdez said. "This shows me that this is the beginning. I'm starting to see the reason, and it's to help others."

Video accompanying this release captures the moment Valdez learned he had been selected as the $10,000 Amped Summer Grand Prize winner. The Grand Reveal can be viewed here.

Amped Summer gave the brand a new way to experience its community through the people living it every day. What began as a creator challenge became a summer of thousands of perspectives on transformation, perseverance, confidence and progress, surfacing stories Amped Fitness may never have discovered otherwise.

Following Amped Summer, Amped Fitness plans to continue building the Amped Creator Program around the creators, personalities and stories emerging from its growing community.

About Amped Fitness:

Amped Fitness® is a rapidly expanding Experience-Design fitness brand built around immersive training destinations, premium amenities and community-focused experiences. With signature destinations including Amped Arena, The Babe Cave®, Aura Pilates, South Peach, Lunar Escape, Azura Cove, Sweat Cinema and Studio Suites, the brand is transporting members and redefining what a gym should feel like. For more information, visit www.ampedfitness.com.

Media Contact:

Melanie Anderson, Senior Account Manager

Pitch Public Relations

[email protected]

480-225-7148

SOURCE Amped Fitness

Share this article

VIP Play, Inc. Furnishes Investor Presentation for Use in Initial Non-Deal Roadshow

LAS VEGAS, Sept. 9, 2026 /PRNewswire/ -- VIP Play, Inc. (OTCQB: VIPZ) (the "Company") today announced that it is furnishing presentation materials (the "Presentation"), that management intends to use in one or more meetings from time to time with current and potential investors in connection with a non-deal roadshow. The Presentation was furnished to the U.S. Securities and Exchange Commission ("SEC") pursuant to Regulation FD, and attached as Exhibit 99.1 to a Current Report on Form 8-K also furnished to the SEC.

The Presentation is being made available to potential investors solely for informational purposes in connection with the non-deal roadshow. It does not constitute, and should not be construed as, an offer to sell, or a solicitation of an offer to buy, any securities of the Company, and does not constitute an offer, solicitation, or sale in any jurisdiction where such offer, solicitation, or sale would be unlawful. Any offering of securities by the Company will be made solely pursuant to definitive offering documentation and in accordance with applicable law, including Regulation D under the Securities Act of 1933, as amended. The information furnished under Item 7.01, including Exhibit 99.1, is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not incorporated by reference into any Company filing under the Securities Act or the Exchange Act except as expressly set forth by specific reference in such filing.

"We've spent the last several years learning what actually drives sustained engagement in sports: identity, competition and community. We believe AI gives us an opportunity to take those lessons well beyond traditional wagering and build experiences that create stronger, more valuable relationships between fans and the organizations that serve them. This presentation gives investors a clearer view of where we're headed and how we intend to build that business," said Les Ottolenghi, Chief Executive Officer of VIP Play, Inc.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements identified by words such as "anticipate," "believe," "expect," "intend," "plan," "target," "project," "estimate," "goal," and "will." These statements reflect the Company's current expectations and are subject to significant competitive, regulatory, economic, operational, technological, and execution-related risks and uncertainties that could cause actual results to differ materially from those expressed or implied. Readers should not place undue reliance on these forward-looking statements, and the Company undertakes no obligation to update or revise them except as required by law. For a discussion of factors that could cause actual results to differ materially, see the Company's filings with the SEC, including its Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q.

About VIP Play, Inc.

VIP Play, Inc. (OTCQB: VIPZ) is an AI-powered sports engagement company that helps teams, leagues, events, brands, and sponsors turn fan identity into participation, community, and lasting value. The company's ecosystem of AI-driven products includes always-on AI characters, interactive prediction and competition experiences, personalized fan zones, and behavioral intelligence tools that transform passive audiences into active, connected communities engaging before, during, and after live events. VIP Play originated in sports wagering, where it developed insight into what sustains fan engagement — identity, competition, and community — and has since built technology designed to deepen those relationships and generate first-party behavioral data for its partners. The company is headquartered in Las Vegas, Nevada.

SOURCE VIP Play, Inc.

Share this article

DELRAY BEACH, Fla., Sept. 9, 2026 /PRNewswire/ -- According to MarketsandMarkets™, the Automotive Adhesives Market size was USD 9.27 billion in 2026 and is projected to reach USD 12.36 billion by 2031, at a CAGR of 5.91% between 2026 and 2031.

Browse 292 market data Tables and 64 Figures spread through 273 Pages and in-depth TOC on "Automotive Adhesives Market - Global Forecast to 2031"

Automotive Adhesives Market Size & Forecast:

- Market Size Available for Years: 2023-2031

- 2026 Market Size: USD 9.27 billion

- 2031 Projected Market Size: USD 12.36 billion

- CAGR (2026-2031): 5.91%

Automotive Adhesives Market Trends & Insights:

- The automotive adhesives market is projected to grow steadily over the next decade, supported by advancements in adhesive chemistry and the shift toward lightweight and electrified vehicles. Automotive manufacturers are increasingly adopting adhesives to improve structural performance, reduce vehicle weight, and simplify assembly processes, making them valuable across body, interior, exterior, powertrain, and battery applications. Growing emphasis on fuel efficiency, electric mobility, material integration, and manufacturing automation further strengthens the role of automotive adhesives as an essential bonding solution, supporting broad industrial adoption.

- Asia Pacific dominated the global automotive adhesives market in 2025, accounting for a share of 59.3%, in terms of value.

- By vehicle type, the passenger car segment dominated the overall automotive adhesives market, accounting for a share of 70.7% in 2025.

- By resin type, the polyurethane segment led the overall automotive adhesives market, accounting for a share of 30.6% in 2025.

- The power train segment is projected to register the highest CAGR of 7.45%, in terms of value, during the forecast period.

- Henkel AG & Co. KGaA, 3M Company, Sika AG, Arkema S.A., and H.B. Fuller Company are identified as key players in the global automotive adhesives market. These companies have strong market presence and extensive product portfolios.

- DELO Industrial Adhesives, Master Bond Inc., and Permabond, among other emerging players, hold strong positions in specialized niche segments, underscoring their potential to become future market leaders in the automotive adhesives market.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=36961165

The growing use of advanced materials is creating a distinct requirement for compatible automotive adhesive systems. Modern vehicles increasingly incorporate materials selected for specific strength, durability, appearance, corrosion resistance, or weight characteristics. These materials often have different surface properties, thermal expansion rates, and joining requirements. Adhesives provide manufacturers with greater flexibility when assembling such material combinations because bonding does not require the same physical joining conditions as processes such as welding. Adhesive suppliers are developing formulations with improved adhesion to plastics, composites, coated metals, and other automotive substrates. Better surface preparation and primer technologies are also expanding material compatibility. As vehicle manufacturers continue diversifying their material choices, adhesive selection is becoming an important part of assembly engineering. This material shift is supporting demand for automotive adhesives with broader substrate compatibility and consistent performance across complex vehicle assemblies.

By vehicle type, the LCV segment held the second-largest share of the automotive adhesives market, in terms of value, in 2025.

The LCV segment held the second-largest share in the automotive adhesives industry, in terms of value, in 2025, with fleet-oriented vehicle production supporting adhesive consumption. Delivery vans, service vehicles, and other commercial fleets require consistent manufacturing processes that support high output and repeatable quality. Adhesives can contribute to faster assembly by reducing the number of separate joining operations required for selected components. Their application can also support automated dispensing across repeated production cycles, helping manufacturers maintain consistent material placement. This is particularly valuable for LCV programs produced in large batches for logistics, retail, maintenance, and service operations. As fleet operators expand standardized vehicle purchases, manufacturers are placing greater focus on efficient production methods. Adhesive systems that support automated application, controlled curing, and repeatable bonding performance are therefore gaining relevance within LCV assembly lines.

By resin type, the epoxy segment accounted for the second-largest share of the automotive adhesives market, in terms of value, in 2025.

The epoxy resin type accounted for the second-largest share in the automotive adhesives market, in terms of value, in 2025, supported by growing use in battery electric vehicles. Epoxy adhesives are relevant for battery pack components because they can bond enclosure parts while providing electrical insulation. Their use can help secure battery modules and support components within spaces. Thermal management is another area, with specially designed epoxy systems helping maintain controlled heat movement around battery parts. Demand for battery safety and component positioning is encouraging manufacturers to select adhesive materials with consistent bonding performance. As electric vehicle production expands across commercial platforms, epoxy suppliers are developing formulations suited to battery assembly processes. This application is creating a growth path for epoxy adhesives.

By application, the paintshop segment held the second-largest market share in 2025.

The paintshop application accounted for the second-largest share in the automotive adhesives market, in terms of value, in 2025. Paintshop operations are driving adhesive demand through bonding of exterior trim, emblems, badges, decorative elements, protective components, and glass-related parts after coating stages. Adhesives support clean attachment while preserving painted surfaces and vehicle appearance. Their use enables manufacturers to limit visible fasteners, helping create smooth body designs demanded by vehicle brands. Paintshop processes require products that remain stable across curing temperatures and handling steps. Adhesive suppliers are developing formulations compatible with coated metals, plastics, composites, and painted substrates. Growing model variety increases demand for bonding solutions for different vehicle designs, surface finishes, and production layouts across passenger cars and commercial vehicles.

Inquiry Before Buying: https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=36961165

Europe was the second-largest market for automotive adhesives, in terms of value, in 2025.

Europe held the second-largest share of the global automotive adhesives market, in terms of value, in 2025, with advanced manufacturing automation supporting wider adhesive adoption across vehicle plants. European automotive factories increasingly use robotic dispensing, automated inspection, controlled curing, and digital production systems to improve process accuracy. Automotive adhesives fit well with these systems because dispensing equipment can control bead size, placement, and material volume with high consistency. Automated application also supports repeatable assembly across large production runs and multiple vehicle platforms. Adhesive manufacturers are developing products compatible with robotic equipment, shorter processing cycles, and automated quality checks. Greater automation across European assembly facilities is creating demand for adhesive grades designed for controlled application and predictable curing. This trend strengthens the role of adhesives within modern automotive production systems.

Key Players

Leading players in the automotive adhesives companies include Henkel AG & Co. KGaA (Germany), 3M Company (US), Sika AG (Switzerland), Arkema S.A. (France), H.B. Fuller Company (US), DuPont de Nemours, Inc. (US), PPG Industries, Inc. (US), Huntsman International LLC (US), Parker-Hannifin Corporation (US), and Illinois Tool Works Inc. (US), among others.

Investment Funding

The automotive adhesives market is witnessing steady investment activity, driven by capacity expansions, product innovation, electric vehicle (EV) development, lightweighting initiatives, and regional manufacturing investments. Manufacturers are investing in high-performance structural adhesives, battery bonding technologies, thermal management solutions, and advanced curing systems to meet growing demand from passenger vehicles, commercial vehicles, and electric vehicle manufacturers. Investment is also increasing in lightweight, low-emission, and high-durability adhesive solutions as automakers focus on vehicle weight reduction, battery performance, manufacturing efficiency, and improved vehicle durability.

Revenue Shift

The automotive adhesives market is undergoing a revenue shift from conventional mechanical fastening and general-purpose bonding toward higher-value adhesive solutions used in electric vehicles, lightweight vehicle structures, battery packs, body-in-white applications, and interior and exterior components. The global automotive adhesives market is projected to grow from USD 9.27 billion in 2026 to USD 12.36 billion by 2031, at a CAGR of 5.91%. Growth is increasingly supported by structural adhesives, polyurethane (PU) adhesives, epoxy adhesives, and acrylic adhesives that provide high strength, durability, vibration resistance, and compatibility with mixed-material vehicle structures.

TORONTO, Sept. 9, 2026 /PRNewswire/ -- Canada Nickel Company Inc. ("Canada Nickel" or the "Company") (TSXV: CNC) (OTCQB: CNIKF) today announced that the Company has filed on SEDAR+ the independent technical reports (the "Reports") prepared in accordance with National Instrument 43-101 – Standards of Disclosure for Mineral Projects ("NI 43-101") supporting the initial mineral resource estimate for its 100% owned Nesbitt Nickel Sulphide Project ("Nesbit") and the updated mineral resource estimate for the 100% owned Deloro Nickel Sulphide Project ("Deloro") near Timmins, Ontario. There are no material differences in the Report from those results disclosed in the Company's news release dated July 23, 2026. The Mineral Resource Estimate, effective as of July 23, 2026, was prepared following the CIM Definition Standards for Mineral Resources and Reserves (November 29, 2019).

The two full technical reports, issued September 8, 2026 and with Mineral Resource Estimates having an effective date of July 23, 2026, are titled "National Instrument 43-101 Mineral Resource Estimate and Technical Report for the Deloro Ni-Co-Pd-Pt Deposit, Deloro Nickel Sulphide Project", and "National Instrument 43-101 Initial Mineral Resource Estimate and Technical Report for the Nesbitt Ni-Co-Pd-Pt Deposit, Nesbitt Nickel Sulphide Project" The Reports were prepared for Canada Nickel by Caracle Creek International Consulting Inc. and can be found under the Company's issuer profile at SEDAR+ www.sedarplus.com.

Qualified Person

Stephen J. Balch P.Geo. (ON), VP Exploration of Canada Nickel and a "qualified person" as defined in NI 43-101, has reviewed and approved the scientific and technical information in this news release.

About Canada Nickel Company

Canada Nickel Company Inc. is advancing the next generation of nickel-sulphide projects to deliver nickel required to feed the high growth electric vehicle and stainless-steel markets. Canada Nickel Company has applied in multiple jurisdictions to trademark the terms NetZero NickelTM, NetZero CobaltTM, NetZero IronTM and is pursuing the development of processes to allow the production of net zero carbon nickel, cobalt, and iron products. Canada Nickel provides investors with leverage to nickel in low political risk jurisdictions. Canada Nickel is currently anchored by its 100% owned flagship Crawford Nickel-Cobalt Sulphide Project in the heart of the prolific Timmins-Cochrane mining camp. For more information, please visit www.canadanickel.com.

For further information, please contact:

Mark Selby

CEO

Phone: 647-256-1954

Email: [email protected] 

Cautionary Note and Statement Concerning Forward Looking Statements

This press release contains certain information that may constitute "forward-looking information" under applicable Canadian securities legislation. Forward looking information includes, but is not limited to, the potential of the Midlothian and Bannockburn Projects, the significance of drill results, the ability to continue drilling, the impact of drilling on the definition of any resource, timing and completion (if at all) of additional mineral resource estimates, the potential of the Timmins Nickel District, strategic plans, including future exploration and development plans and results, and corporate and technical objectives. Forward-looking information is necessarily based upon several assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking information. Factors that could affect the outcome include, among others: future prices and the supply of metals, the future demand for metals, the results of drilling, inability to raise the money necessary to incur the expenditures required to retain and advance the property, environmental liabilities (known and unknown), general business, economic, competitive, political and social uncertainties, results of exploration programs, risks of the mining industry, delays in obtaining governmental approvals, failure to obtain regulatory or shareholder approvals. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. Accordingly, readers should not place undue reliance on forward-looking information. All forward-looking information contained in this press release is given as of the date hereof and is based upon the opinions and estimates of management and information available to management as at the date hereof. Canada Nickel disclaims any intention or obligation to update or revise any forward-looking information, whether because of new information. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE Canada Nickel Company Inc.

Share this article

Point 41 Capital Partners and Management Recapitalize Safe-Way Garage Doors to Support the Company's Next Phase of Growth

GREENWICH, Conn., Sept. 9, 2026 /PRNewswire/ -- Point 41 Capital Partners ("Point 41"), a middle-market private equity firm, today announced a partnership with Safe-Way Garage Doors, LLC ("Safe-Way" or the "Company"), acquiring the Company from CW Industrial Partners ("CWI") and partnering with management to support Safe-Way's next phase of growth. Terms of the private transaction were not disclosed.

Headquartered in Warsaw, IN, Safe-Way is a leading manufacturer and distributor of highly customizable residential and commercial overhead garage doors and related products, serving a diversified base of customers across the United States through a nationwide footprint of manufacturing facilities and distribution centers. Founded in 1959, Safe-Way has built a longstanding reputation for quality, product breadth and customization capabilities, industry-best lead times, and high-touch customer service.

"For more than 60 years, Safe-Way has earned the trust of its customers by delivering high-quality products and exceptional service," said Ted Rock, Chief Executive Officer of Safe-Way. "Our partnership with Point 41 provides us with the support and resources to build upon our strong foundation, create even greater value for our existing customers, and bring the Safe-Way value proposition to more customers across the country."

"We are excited to partner with Ted and the Safe-Way team to accelerate the Company's growth," said Aaron Wolfe, Managing Partner of Point 41. "We have been impressed by the management team's track record of execution and its clear vision for the business. We believe Safe-Way is well positioned to continue gaining market share, and we look forward to supporting the team as it deepens its presence in core markets, expands into new geographies, and broadens its product portfolio."

"Our team has significant experience investing in and growing leading building products companies, making Safe-Way a natural fit with Point 41's strategy," said Jordan Wadsworth, Managing Partner of Point 41. "The Company's customer-centric approach and strong market position create meaningful opportunities for continued growth, and we look forward to leveraging our experience and resources to support the team in realizing Safe-Way's full potential."

Safe-Way is actively seeking partnerships with leading residential and commercial overhead door manufacturers and distributors. Founders, owners, and managers are encouraged to contact Point 41 to learn more about partnering with Safe-Way.

Klehr Harrison Harvey Branzburg LLP, K&L Gates LLP, and Kirkland & Ellis LLP served as legal advisors to Point 41. William Blair & Company served as exclusive financial advisor to Point 41.

KeyBanc Capital Markets served as exclusive financial advisor to Safe-Way and Calfee, Halter & Griswold LLP served as legal advisor to CWI and Safe-Way on the transaction.

About Point 41 Capital Partners

Point 41 Capital Partners is a middle-market private equity firm that partners with management teams in the specialty industrials and services sectors and invests in North American-based companies with an enterprise value between $50 million and $350 million. Point 41's ideology is built upon four key principles – team, expertise, execution, and integrity – that guide the firm's investment philosophy. In alignment with management teams, Point 41 offers 40 years of deep sector expertise and a proven approach to driving transformational growth. For more information, please visit www.point41capital.com and follow us on LinkedIn.

Media Contacts

Ted Rock, CEO, Safe-Way Garage Doors

Ankur Bhargava, Principal, Point 41 Capital Partners

SOURCE Point 41 Capital Partners, L.P.

Share this article

Since joining Natilus in 2022 as Head of Business Development, Nolan has played a central role in building the commercial foundation for Natilus' blended-wing-body aircraft, KONA and HORIZON EVO. Under his guidance, the company has secured reservation agreements with operators including Ameriflight and Nolinor Aviation, building the commercial order book to 570+ aircraft pre-orders.

His promotion comes as global demand accelerates for fuel-efficient, lower-emission aircraft capable of operating within existing airport infrastructure. Natilus' blended-wing-body design delivers substantial reductions in fuel burn and operating costs alongside greater volumetric capacity than traditional tube-and-wing aircraft. These advantages are driving strong interest from cargo and passenger operators alike as the industry works to meet rising capacity commitments.

"As we build an entirely new category of aircraft that promises to reshape the future of flight for commercial, cargo and defense markets, there isn't a more exciting opportunity in the aviation industry," said Nolan Giblin, COO of Natilus. "I'm invigorated by the role I play in bringing KONA and HORIZON EVO to commercialization and inspired by the opportunities ahead."

With a bachelor's degree from the University of San Diego and an MBA from San Diego State University, Nolan is a tenured aerospace professional with nearly two decades of business development and operations experience. Prior to joining Natilus, he held roles in business management and strategic finance across major defense aviation programs, including at Northrop Grumman and General Atomics, building the operational and financial discipline he now brings to scaling Natilus' commercial and defense aircraft programs.

"Since Nolan joined in 2022, the company has undergone dramatic growth, due in large part to Nolan's strategic vision and organizational prowess," said Aleksey Matyushev, CEO of Natilus. "As we enter this next chapter, I couldn't have a better partner to drive our business operations forward, ensure our priorities stay aligned and scale both the organization and our family of aircraft. Nolan is exactly the type of visionary needed to transform our vision of a blended-wing-body aircraft into a commercial reality."

About Natilus

Natilus is a U.S.-based company developing a family of hyper-efficient blended-wing-body (BWB) aircraft designed to transport people and cargo more sustainably and efficiently than ever before. With over 570+ aircraft pre-orders valued at $24 billion, Natilus is commercializing its BWB aircraft that unlock improved aviation economics – reducing fuel consumption by 30% and operational costs by 50% while increasing payload capacity by 40%. Founded in 2016, the Natilus team is composed of innovators from Boeing, General Atomics, Northrop Grumman, Skunkworks, SpaceX, and Piper Aircraft. Learn more at natilus.co.

SOURCE Natilus

Share this article

COLLEGE STATION, Texas, Sept. 9, 2026 /PRNewswire/ -- Matica Biotechnology ("Matica Bio"), a Texas-based contract development and manufacturing organization (CDMO) specializing in cell and gene therapy, today announced a collaboration with Bondwell Technologies, an innovative Texas biotechnology company developing next generation technologies for bioprocessing and advanced life science applications.

The collaboration underscores the continued growth of the Texas biotechnology ecosystem and demonstrates the value of connecting emerging innovators with experienced development partners to accelerate technology advancement within the state.

"As Texas continues to establish itself as a leading hub for biotechnology innovation, collaborations between homegrown companies are becoming increasingly important," said Paul Kim, CEO of Matica Bio. "We are proud to support fellow Texas biotechnology companies as they advance innovative technologies and strengthen the state's life sciences ecosystem."

Bondwell Technologies, headquartered in College Station, is developing proprietary protein technologies with applications in bioprocessing and life sciences. Through this collaboration, Matica Bio will provide development expertise to help advance Bondwell's manufacturing readiness and support future commercialization objectives.

The collaboration reflects a shared commitment to fostering innovation in Texas by leveraging local scientific expertise, manufacturing capabilities, and strategic partnerships. By working together, both organizations contribute to strengthening the state's growing biotechnology infrastructure while helping innovative technologies progress toward commercial impact.

" A new technology does not get adopted because the company that built it says it works. It gets adopted when a manufacturer runs it on their own equipment and reports what happened," said David Howell, PhD, Chief Executive Officer of Bondwell Technologies."Having that development expertise nearby is what makes it practical to build this technology in Texas."

Over the past several years, Matica Bio has continued to expand its presence within the Texas biotechnology landscape, supporting both Texas based and national biotechnology companies through development and manufacturing services. The company remains committed to attracting advanced biotechnology programs to Texas while helping local innovators access world class development capabilities without leaving the state.

This collaboration further reinforces the momentum of Texas as an emerging destination for biotechnology innovation, where research institutions, startup companies, technology developers, and manufacturing organizations are working together to accelerate the development of next generation life science technologies.

About Bondwell Technologies

Bondwell Technologies is a Texas biotechnology company developing innovative protein technologies. The first application of this technology is licensed to BioPure, Inc. for bioprocessing applications. The company's proprietary platform is focused on enabling next-generation manufacturing and purification solutions that support the broader biopharmaceutical industry.

About Matica Biotechnology, Inc.

Matica Biotechnology is a viral vector Contract Development and Manufacturing Organization (CDMO) that leverages advanced technologies at its purpose-built cGMP facility. With industry-leading expertise in process development, assay development, and cGMP manufacturing, Matica Bio serves as a trusted partner, seamlessly supporting its clients with streamlined operations throughout every stage of projects. Collaborating across five Matica sites worldwide, Matica Bio delivers excellence in the CDMO domain through innovations such as MatiMax™ proprietary cell lines, in-line process monitoring, and single-use technologies.

In addition to its manufacturing and development capabilities, Matica Bio supports integrated investigator-initiated trial (IIT) and translational development programs through collaborative global platform models that connect U.S.-based manufacturing with leading international clinical ecosystems. These integrated frameworks are designed to accelerate early clinical development, enable globally credible clinical datasets, and support scalable pathways from translational research to global clinical expansion.

Visit www.maticabio.com for more information.

SOURCE Matica Biotechnology, Inc.

Share this article

Latest Clearance Expands VERAFEYE's Capabilities as the Company Prepares for Commercial Launch in Early 2027

DUBLIN, Sept. 9, 2026 /PRNewswire/ -- LUMA Vision, a medtech company transforming minimally invasive cardiac procedures, today announced FDA clearance expanding the capabilities of VERAFEYE, its procedural intelligence platform. The news marks another significant step toward the company's vision for the cardiac lab of the future, where imaging, visualization, navigation, and guidance operate as a single integrated system, giving physicians continuous real-time visibility into the interplay of anatomy, devices, and therapy delivery.

With this clearance, VERAFEYE unifies digital anatomy creation, catheter tracking, and guidance on a single platform, revealing true anatomy in real time, analyzing it as the procedure unfolds, and guiding the physician to every target along the way. The system reconstructs 3D models of the left and right atria with CT-like accuracy, allows physicians to visualize and document ablation delivery directly on the anatomy, and maintains continuous visibility of both imaging and ablation catheters through electromagnetic tracking and automated imaging.

"What stands out about VERAFEYE is its ability to combine real-time imaging, visualization, and catheter tracking into a single integrated AI-driven platform," said Dr Devi Nair, Chief of Cardiac Electrophysiology & Research at St. Bernards Healthcare and Arrhythmia Research. "Rather than requiring physicians to piece together information from multiple sources, the system continuously provides anatomical and procedural context in real time without the need for repositioning of the imaging catheter. That represents an important step toward a more intelligent and connected approach to guiding cardiac procedures."

Delivering Procedural Intelligence: How VERAFEYE is the Foundation of the Cardiac Lab of the Future

- Imaging: VERAFEYE uses a single 360° imaging catheter to capture raw ultrasound data and construct real-time 2D and 3D anatomy of the heart.

- Visualization: VERAFEYE builds a live anatomical map of the heart, valves, great vessels, and surrounding structures, giving physicians a complete real-time view of the patient's anatomy.

- Navigation: VERAFEYE maintains continuous tracking of both the imaging and ablation catheters, so physicians never have to stop and manually reposition to keep the ablation catheter in view, allowing them to stay focused on treating the patient.

- Guidance: VERAFEYE lets physicians mark locations directly on the anatomical model as ablation therapy is delivered, confirming alignment and increasing confidence without compromising efficiency. As VERAFEYE builds a database of real anatomy across thousands of cases, expanded guidance will be available in the future to physicians, with the goal of helping them decide, not just see.

"This clearance is another step toward the cardiac lab of the future and our commercial launch of VERAFEYE in early 2027," said Fionn Lahart, CEO and co-founder of LUMA Vision. "By bringing imaging, visualization, navigation and guidance together into a single platform, VERAFEYE delivers significant clinical impact with virtually no workflow disruption. It's a new paradigm for guiding arrhythmia procedures, and just the beginning of our procedural intelligence platform, which will be expanded into LAA and structural heart."

To learn more about VERAFEYE, visit www.lumavision.com.

About LUMA Vision

LUMA Vision is a privately held, medical device company based in Dublin, Ireland. LUMA Vision designs and develops cutting edge innovative technologies to significantly advance healthcare and solve truly global unmet clinical needs. VERAFEYE™ is a novel ultrasound based cardiac visualization and navigation platform for generating a 360-degree view, navigating and imaging all structures and devices around the catheter with an unprecedented field of view. With a commitment to advancing patient care, LUMA Vision focuses on delivering groundbreaking products that enhance clinical outcomes and improve lives around the world. LUMA Vision was founded by CEO Fionn Lahart and CTO Christoph Hennersperger. Learn more about LUMA Vision and VERAFEYE™ at www.lumavision.com

SOURCE LUMA Vision

Share this article

TYRA's mission is to make dabogratinib the clear first-line treatment choice for patients with LG IR NMIBC

Favorable safety and tolerability results support chronic dosing potential

No clinically significant hyperphosphatemia, nail toxicity or ocular toxicity; low frequency of transaminase TEAEs (10%); Grade 3 treatment-related AEs in fewer than 5% of patients (none at 60 mg QD)

79% ORR and 64% best overall response CR rate with 60 mg QD in combined single and multiple marker lesion patients (n=14), with 100% ORR and 75% best overall response CR rate with 60 mg QD in single marker lesion patients (n=8), supporting planned adjuvant Phase 3 strategy

First patient treated in Phase 2 SURF303 study in LG UTUC achieved a 3-month CR with 60 mg QD

Conference call today, September 9, at 8 am ET to discuss results

CARLSBAD, Calif., Sept. 9, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced initial results from SURF302, its Phase 2 study evaluating oral dabogratinib in patients with FGFR3-altered low-grade intermediate-risk non-muscle invasive bladder cancer (LG IR NMIBC). The study provided clinical proof of concept for selective oral FGFR3 inhibition and identified 60 mg once-daily (QD) as the potential dose supporting TYRA's planned registrational adjuvant development strategy.

Approximately 70% of patients with LG IR NMIBC do not receive adjuvant therapy intended to reduce recurrence, despite evidence that intravesical treatment lowers recurrence risk. Instead, many patients choose surveillance, or "watch and wait", because existing therapies involve repeated catheterization and office-based procedures that can make the burden of treatment outweigh its perceived benefit. TYRA believes oral dabogratinib, if approved, has the potential to change that paradigm by offering patients a convenient, once-daily oral therapy.

"We are extremely excited to report initial results from SURF302 today as we work to advance what we believe could become the first once-daily oral therapy for patients with low-grade IR NMIBC," said Todd Harris, Ph.D., Chief Executive Officer of TYRA Biosciences. "These results belong first and foremost to the patients participating in SURF302 and the investigators and study teams who have made this research possible. We're incredibly grateful for their partnership."

"SURF302 has effectively given us two studies in one, informing dual settings in which dabogratinib could potentially be used. Patients with a single marker lesion — whose minimal disease most closely mirrors the adjuvant setting (where no tumor is left behind) and historical marker lesion studies — achieved a 100% overall response rate (ORR) (8/8) with 60 mg QD, including a 75% complete response (CR) rate as best overall response (BOR), demonstrating the activity of this dose for our planned Phase 3 adjuvant study," said Doug Warner, M.D., Chief Medical Officer of TYRA. "Patients with multiple marker lesions carry a higher tumor burden, more representative of an ablative setting, and our preliminary exposure-response analyses suggest that higher drug exposure may be important there. Dabogratinib's favorable safety results to date give us the opportunity to evaluate a higher dose in that setting. Taken together, these data have meaningfully expanded our understanding of dabogratinib as we look to continue to advance development into Phase 3 studies."

"As a community-based urologist, one of the greatest challenges isn't identifying patients who could benefit from therapy—it's that many choose surveillance because the burden of repeated catheterization and intravesical treatments outweighs the perceived benefit," said Mark Silva, M.D., Greater Boston Urology. "Too often, those patients are simply waiting to recur. A well-tolerated once-daily oral therapy could fundamentally change that conversation – giving patients an option they may be more willing to accept, and giving physicians the chance to intervene before the next recurrence rather than react after it occurs."

Initial safety and tolerability results. As of the August 31, 2026 data cutoff, initial safety and tolerability results for oral dabogratinib were favorable across the 60 mg QD (n=22) and 50 mg QD (n=22) dose cohorts. Most treatment-emergent adverse events (TEAEs) were Grade 1 or 2, with Grade 3 TEAEs in 3 participants (14%) at 60 mg and 2 participants (9%) at 50 mg. Grade 3 treatment-related AEs occurred in 2 of 44 participants (4.5%) across both cohorts, both at 50 mg QD, with none at 60 mg QD. There were no Grade 4 or 5 TEAEs. TYRA believes these results are consistent with the potential for chronic once-daily administration.

- At 60 mg QD, there were no dose reductions or treatment-related discontinuations.

- No clinically significant hyperphosphatemia, nail toxicity, or ocular toxicity was observed.

- TEAEs were generally manageable. 

- Transaminase TEAEs were observed at low frequency ( 10%).

- The most frequently reported TEAEs at 60 mg QD were fatigue, diarrhea and dry eye. Diarrhea was generally Grade 1, transient, and limited.

Initial efficacy results. As of the August 31, 2026 data cutoff, 26 participants were evaluable for efficacy across the 60 mg QD (n=14) and 50 mg QD (n=12) cohorts (participants who received study treatment and had undergone at least the month 3 disease assessment). All responses below are subject to change with continued treatment and follow-up.

Combined Single and Multiple Marker Lesion Response

Single Marker Lesion Response

- All 3-month CRs with 6-month assessments remained in response at 6 months (n=5).

- The first participant in the study remained in CR at 12 months and continued on study drug at 14 months.

Dose-optimization and registrational strategy.

- Preliminary exposure-response analyses across the 50 mg QD and 60 mg QD cohorts showed an ORR of 86% (12/14) among participants with a target steady-state exposure above the AUC threshold of 2500 ng‧hr/mL, compared with 58% (7/12) among participants below the threshold. The exposure-response relationship was most apparent among participants with multiple marker lesions, while responses in participants with a single marker lesion occurred across the observed exposure range — supporting 60 mg QD in the planned adjuvant setting, where disease burden is minimal, and the evaluation of a higher dose in the ablative setting.

- TYRA plans to complete enrollment in the 60 mg QD cohort and initiate a 70 mg QD cohort to explore dabogratinib in the ablative setting. TYRA also plans to engage health authorities on Phase 3 study design and dose selection and, subject to that feedback, to continue preparations for a planned registrational adjuvant study.

Initial observation from SURF303 in LG UTUC. In SURF303, TYRA's Phase 2 study evaluating oral dabogratinib in patients with low-grade upper tract urothelial cancer (LG UTUC), the first patient treated achieved a complete response at the 3-month assessment with 60 mg QD, with no observed TEAEs and remained on study drug as of the August 31, 2026 data cutoff.

Conference Call and Webcast

TYRA is hosting a conference call and webcast today, September 9, 2026, at 8:00 am ET to discuss the initial SURF302 study results with oral dabogratinib. Participants may access a live webcast of the call and the associated slide presentation following the conclusion of the call on the "For Investors" page of the TYRA website at https://ir.tyra.bio. To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. A replay of the conference call and webcast will be archived on the Company's website for at least 90 days.

About SURF302

SURF302 (NCT06995677) is a Phase 2, multicenter, open-label clinical study evaluating the efficacy and safety of oral dabogratinib in adults with FGFR3-altered low-grade IR NMIBC. The study includes dose-optimization cohorts and is designed to support the potential development of dabogratinib as an adjuvant therapy. Key endpoints include best overall response, complete response at three months, time to recurrence, duration of response, recurrence-free survival, progression-free survival, safety and tolerability. For more information, please visit the Patients page of the Company's website at https://tyra.bio/patients/ or https://clinicaltrials.gov/study/NCT06995677.

About Intermediate-Risk Non-Muscle Invasive Bladder Cancer (IR NMIBC)

Bladder cancer is one of the most common cancers in the United States, with more than 760,000 people living with the disease. Many patients are diagnosed with intermediate-risk non-muscle invasive bladder cancer (IR NMIBC), a disease characterized by frequent tumor recurrence that often requires repeated surveillance and surgical intervention over many years. Current treatment typically includes transurethral resection of bladder tumor (TURBT) followed by intravesical chemotherapy administered through repeated bladder catheterization. Despite evidence that adjuvant intravesical therapy can reduce recurrence, approximately 70% of patients with LG IR NMIBC do not receive treatment intended to prevent recurrence, highlighting a significant unmet medical need for more accessible and better-tolerated treatment options. Dabogratinib is the only investigational oral FGFR3-selective therapy currently in clinical development for patients with FGFR3-altered IR NMIBC.

About Dabogratinib

Dabogratinib is TYRA's lead precision medicine candidate stemming from its in-house SNÅP platform.